The breast cancer, early disease: toxicity from therapy with epirubicin regimens - cardiac assessment and risk evaluation (BETTER-CARE) study: CMR with early gadolinium relative enhancement, but not high-sensitivity troponin T, predicts the risk of chronic anthracycline cardiotoxicity
Main Authors: | Kotwinski Paul, Smith Gillian, Sanders Julie, Ma Louise, Cooper Jackie, Thomas Michael, Mythen Michael (Monty) G, Jones Alison, Montgomery Hugh E, Pennell Dudley J |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2013-01-01
|
Series: | Journal of Cardiovascular Magnetic Resonance |
Similar Items
-
CMR shows that anthracycline cardiotoxicity is common in women treated for early breast cancer and associated with undiagnosed hypertension; but cannot be reliably detected using late-gadolinium enhancement imaging
by: Kotwinski Paul, et al.
Published: (2013-01-01) -
Cardiovascular magnetic resonance imaging in early anthracycline cardiotoxicity
by: Hugh Montgomery, et al.
Published: (2009-01-01) -
Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
by: Paul Kotwinski, et al.
Published: (2016-01-01) -
Cardiac troponin T for early detection of cardiotoxicity in breast cancer patients treated with epirubicin
by: Erdim Refik, et al.
Published: (2009-09-01) -
The Breast Cancer, Early Disease: Toxicity from Therapy with Epirubicin Regimens – Cardiac Assessment and Risk Evaluation (BETTER-CARE) Study : design, set-up and analysis of a prospective multicentre collaboration to investigate the pharmacogenetics of anthracycline cardiotoxicity, using cardiovascular magnetic resonance imaging
by: Kotwinski, P. J.
Published: (2013)